CSCamilla Satragno

Camilla Satragno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camilla Satragno has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Influence of Fractionation and Beam Sequencing on Absorbed Dose to Circulating Lymphocytes During Ultra-High Dose Rate and Conventional Radiotherapy: An In Silico Study

    by François de Kermenguy, Camilla Satragno, Mohammed El-Aichi, Ibrahima Diallo, Cristina Veres, Fereshteh Talebi, Cathyanne Schott, Eric Deutsch, Charlotte Robert

    PURPOSE: Several in silico models concluded that ultra-high dose rate (UHDR) radiotherapy could spare large quantities of circulating lymphocytes. However, preclinical studies failed to show a reduction in radiation-induced lymphopenia after UHDR irradiation compared with conventional dose rates (CONV). This study aims to investigate the influence of fractionation and beam sequencing on absorbed dose to circulating lymphocytes during CONV and UHDR irradiations. MATERIALS AND METHODS: The LymphoDose framework was applied to a cohort of 162 patients treated for brain tumors with 3D conformal radiotherapy. Four scenarios of UHDR treatment were compared: (S1) one fraction with all beams delivered simultaneously, (S2) one fraction with sequentially delivered beams, (S3) three fractions with all beams delivered simultaneously, and (S4) three fractions with sequentially delivered beams. RESULTS: UHDR fractionation and the beam delivery scheme had a significant impact on irradiated blood volume (1.3% ± 0.1% for S1 v 13% ± 3.2% for S4) and lymphocyte pool (12.5% ± 0.1% for S1 v 32.8% ± 0.2% for S4). UHDR scenarios primarily irradiate lymphocytes through exposure of head-and-neck lymph node rather than circulating blood. CONV and UHDR result in distinct temporal dose patterns for lymphocytes, characterized by either numerous low-dose fractions or a few high-dose pulses. CONCLUSION: The doses delivered to lymphoid organs account for a substantial portion of the total dose received by the lymphocyte pool, showing only a limited difference between UHDR and CONV in terms of lymphocyte exposure. The fractionation strategy of UHDR irradiation beams could play an important role in successfully translating UHDR treatments into clinical practice.


  • Open Access

    Scalp segmentation and permanent alopecia prediction in pediatric craniospinal irradiation: The PAST and HOPE projects

    by Camilla Satragno, Gianluca Piccolo, Federica Picichè, Mattia Barboro, Irene Schiavetti, Sucheeta Campora, Alessandro Alparone, Stefania Zara, Daniele Zefiro, Francesca Cavagnetto, et al.

  • Open Access

    Review of: "Strategies for Management and Long-term Surveillance of Pediatric Differentiated Thyroid Cancer: Balancing Efficacy and Quality of Life"

    by Camilla Satragno

    GENERAL COMMENTS The author has undertaken a narrative review to discuss the management of pediatric differentiated thyroid cancer (DTC), focusing particularly on guidelines from China and the United States. The objective to provide a detailed overvi...

  • Open Access

    An Innovative Approach to Scalp Segmentation in Pediatric Brain Radiotherapy: An Atlas-Based Study

    by C. Satragno, M. Barboro, A. Alparone, G. Fiorella, M. Turazzi, S. Campora, S.E. Cena, A. Coco, D. Esposito, A. Ferrero, et al.


  • Open Access

    P11.23.A GLIOBLASTOMA MOLECULAR CORRELATES OF SEIZURE OCCURRENCE/RECURRENCE AFTER SURGERY: THE ROLE OF P53 MUTATION

    by P Mattioli, E Cella, A Donniaquio, R Aloisio, R Mancini, F Calizzano, V Costa, F Villani, C Dellepiane, C Genova, et al.

    The integration of molecular data and histology changed the diagnostic approach and prognostic characterization for patients with brain tumors. The aim of this study is identify molecular risk factors associated with seizure occurrence and/or recurrence after surgery in patients with brain glioblastoma. Patients with brain glioblastoma were consecutively enrolled and underwent brain surgery, followed by histopathological and molecular evaluation. Immuno-histochemical, molecular (synaptophysin, GFAP, ATRX, p53, ki67 index and MGMT gene promoter methylation) and clinical (age, sex and seizure occurrence/recurrence before and/or after surgery) data were collected. Histopathological and molecular features were compared between patients with and without seizure occurrence/recurrence after surgery. A step-backward logistic regression was performed to investigate the association between molecular features and seizure occurrence/recurrence. 100 patients (age 59.51±1.23, 65 males) were enrolled. Forty-nine patients had seizures before surgery. After surgery, 40 patients (age 59.43±1.64, 27 males) had seizure occurrence/recurrence, while 60 (age 59.57±1.75, 38 males) had not. Patients with epilepsy (i.e., seizures before and/or after surgery) had lower synaptophysin (33.33%, p=0.008) and higher p53 (85%, p=0.038) mutation rate compared with patients without epilepsy. In the whole sample, seizure occurrence/recurrence after surgery was significantly associated with p53 mutation (OR: 3.9, CI 1.12-13.50, p=0.032) and seizure occurrence before surgery (OR: 5.3, CI 2.15-13.08, p<0.001). In patients without seizures before surgery, p53 mutation perfectly predicted seizure occurrence, therefore the OR was not computable. In fact, all patients without p53 mutation didn’t have seizure after surgery, while all patients that had seizure after surgery, also had p53 mutation (p=0.028). However, to note 71% patients with p53 mutation didn’t have seizure after surgery. The p53 mutation is related with a high risk of seizure occurrence/recurrence after surgery in brain glioblastoma, even in patients that didn’t have seizures before surgery. Conversely, the absence of p53 mutation appears to protect against the occurrence of seizures. If confirmed, this result may help in the management of anti-seizure treatment after surgery in brain glioblastoma patients.

  • Open Access

    P11.71.B THE MULTIDISCIPLINARY METHOD TO DISTINGUISH TRUE TUMOUR PROGRESSION FROM PSEUDOPROGRESSION IN HIGH GRADE GLIOMA VIA THE SYSTEMIC INFLAMMATORY MARKERS

    by C Satragno, A Ferrero, L Falcitano, E Cella, D Esposito, A Ginulla, F Picichè, L Barletta, L Roccatagliata, M Resaz, et al.

    To identify the role of serum inflammatory markers and T1-gadolinium volume (T1GV) post-radiotherapy (RT), in the multidisciplinary approach to differentiate true tumor progression (TTP) from pseudo-progression (PsP) in high-grade glioma (HGG) patients. A retrospective cohort of HGG (WHO 2021) was consecutively enrolled from 2015 to 2021. Clinical, instrumental, and therapeutic data were collected at diagnosis, treatment and within 6 months after the end of RT.The response to treatment was assessed according to the modified RANO criteria; volumetry of suspected progression was performed on T1G and FLAIR. Blood tests also included the analysis of the neutrophil/lymphocyte ratio (NLR), systemic immune-inflammatory index (SII) and systemic inflammatory response index (SIRI). Patients with suspected progression underwent a new MRI within 3 months of the first one.Any association between the clinicopathological factors and the presence of progression were analysed by Chi-square and Fisher’s exact test. Differences between group in continuous variables were assessed by independent sample-T test or Mann-Whitney U test, as appropriate. Prognostic factors for progression were investigated with a regression logistic model where predictors were log-transformed owing to their skewed distribution. Due to an existing multicollinearity in the common multivariate regression model between the variables “NLR” and “SII index”, two further separate binary regression models were set up, whereby in the “Multivariate Model NLR” the SII index was not considered and in the “Multivariate Model SII index” the NLR was not included. A Cox regression analysis was conducted to assess the impact of PsP- and TTP-related factors on overall survival (OS). 39 patients (41.0% females) were included, 16 showed PsP and 23 TTP.NLR, SII and T1 gadolinium volume were higher in the TTP group than in PsP (respectively 4.7 vs 2.8, p= 0.002; 890.5 vs 546.5, p = 0.009; and 11.7 cm3 vs 2.2 cm3, pOR 2.7, CI 95% 1.3 to 5.5, p=0.006)] and SII [OR 4.2, 95%CI: 1.1 to 15.3, p=0.030].The OS was significantly worsened in patients with TTP compared to patients with PsP [HR 3.97, 95%CI: 1.59 to 9.93, p = 0.003]. At multivariate analysis other factors did not impact the overall survival. Higher NLR, SII and T1GV showed good sensitivity and specificity to differentiate between PsP and TTP.Further studies with larger cohorts are needed to evaluate the inclusion of inflammatory indices and volumetry in the differentiation diagram of PsP from TTP.